QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.07%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.07%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.07%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.07%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
Log in
NASDAQ:IONS

Ionis Pharmaceuticals Stock Forecast, Price & News

$50.97
-0.34 (-0.66 %)
(As of 12/3/2020 12:00 AM ET)
Add
Compare
Today's Range
$50.56
Now: $50.97
$51.41
50-Day Range
$45.82
MA: $48.90
$52.51
52-Week Range
$39.32
Now: $50.97
$66.22
Volume520,367 shs
Average Volume912,753 shs
Market Capitalization$7.13 billion
P/E Ratio106.19
Dividend YieldN/A
Beta1.44
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic from ALS; ION859 for Parkinson's disease; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing severe and rare disease products, such as AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-PKK-LRx for hereditary angioedema; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-ENAC-2.5Rx for cystic fibrosis; and ION357 for retinitis pigmentosa. In addition, its cardio metabolic and renal drugs include AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases; AKCEA-ANGPTL3-LRx for cardio metabolic disorders; IONIS-GCGRRx for type 2 diabetes; IONIS-AGT-LRX for the treatment of resistant hyper tension; IONIS-FXI-LRx for clotting disorders; IONIS-AZ4-2.5-LRx for cardiovascular diseases; and ION839 for nonalcoholic steatohepatitis. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; IONIS-HBVRx and IONIS-HBV-LRx for hepatitis B virus infection; and IONIS-FB-LRx for compliment meditated disease. It has a collaboration agreement with AstraZeneca; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Ionis Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IONS
CUSIP46433010
Phone760-931-9200
Employees817

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.12 billion
Cash Flow$2.46 per share
Book Value$11.49 per share

Profitability

Net Income$303.26 million

Miscellaneous

Market Cap$7.13 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$50.97
-0.34 (-0.66 %)
(As of 12/3/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

How has Ionis Pharmaceuticals' stock price been impacted by Coronavirus?

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IONS stock has increased by 3.7% and is now trading at $50.97.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Ionis Pharmaceuticals?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Ionis Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Ionis Pharmaceuticals?

Wall Street analysts have given Ionis Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ionis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Ionis Pharmaceuticals
.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings results on Wednesday, November, 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.11. The company had revenue of $160 million for the quarter, compared to the consensus estimate of $182.14 million. Ionis Pharmaceuticals had a return on equity of 6.57% and a net margin of 7.82%. Ionis Pharmaceuticals's revenue was down 4.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.18 earnings per share.
View Ionis Pharmaceuticals' earnings history
.

What price target have analysts set for IONS?

13 analysts have issued 12 month target prices for Ionis Pharmaceuticals' stock. Their forecasts range from $49.00 to $91.00. On average, they expect Ionis Pharmaceuticals' share price to reach $68.18 in the next year. This suggests a possible upside of 33.8% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals
.

Who are some of Ionis Pharmaceuticals' key competitors?

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the following people:
  • Dr. Stanley T. Crooke, Founder & Exec. Chairman (Age 75, Pay $1.97M)
  • Dr. Brett P. Monia, Founder, CEO & Director (Age 59, Pay $1.06M)
  • Ms. Elizabeth L. Hougen, Exec. VP of Fin. & CFO (Age 58, Pay $834.19k)
  • Mr. Patrick R. O'Neil, Exec. VP of Legal, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 46, Pay $816.23k)
  • Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 66, Pay $1.36M)
  • Dr. Richard S. Geary, Exec. VP of Devel. (Age 62, Pay $829.79k)
  • Mr. Darren Gonzales, Chief Accounting Officer & Sr. VP
  • Dr. C. Frank Bennett, Exec. VP & Chief Scientific Officer (Age 63)
  • Mr. D. Wade Walke, VP of Investor Relations
  • Ms. Roslyn Patterson M.B.A., VP of Marketing & Communications

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.06%), First Trust Advisors LP (1.00%), Wells Fargo & Company MN (0.66%), JPMorgan Chase & Co. (0.52%), Charles Schwab Investment Management Inc. (0.49%) and Pinnacle Associates Ltd. (0.42%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals
.

Which major investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including AJO LP, BlackRock Inc., Dowling & Yahnke LLC, Skandinaviska Enskilda Banken AB publ, Wells Fargo & Company MN, Rothschild & Co. Asset Management US Inc., Morgan Stanley, and Acadian Asset Management LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke.
View insider buying and selling activity for Ionis Pharmaceuticals
.

Which major investors are buying Ionis Pharmaceuticals stock?

IONS stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., ARK Investment Management LLC, Point72 Asset Management L.P., DekaBank Deutsche Girozentrale, Voloridge Investment Management LLC, AXA S.A., Natixis, and First Trust Advisors LP.
View insider buying and selling activity for Ionis Pharmaceuticals
.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $50.97.

How big of a company is Ionis Pharmaceuticals?

Ionis Pharmaceuticals has a market capitalization of $7.13 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis. Ionis Pharmaceuticals employs 817 workers across the globe.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.